A single-pill treatment to suppress HIV proved as effective as existing therapies of up to 11 tablets daily, the latest advance in a scientific “golden age” for treating the virus even as rich ...
ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart, VH184 and VH499.
DENVER -- A daily, single-tablet combination of bictegravir and lenacapavir (Yeztugo) was noninferior to complex multi-tablet ...
In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...
People who have lived with HIV long-term can need up to a dozen pills every day to suppress the virus. Results from a new ...
DOR/ISL is currently at the pre-registration stage of development in the US and is expected to launch in this market in 2026, if approved.
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.
A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...
Dolutegravir plus lamivudine demonstrates noninferiority to the standard-of-care three-drug regimen in treatment-naive patients with HIV without preliminary drug resistance testing. Researchers ...
A therapy originally developed for HIV now provides new options for patients with rare genetic disorders. It’s now possible to use these drugs to address DNA defects and enhance muscle function. This ...
The state invoked emergency rule-making power for what advocates say will be another emergency, when HIV-positive patients lose medication assistance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results